Close Menu

North America

The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.

The GenomeWeb Index underperformed the Dow Jones and the Nasdaq, but outperformed the Nasdaq Biotechnology Index last month.

The US National Institutes of Health and Moderna are enrolling volunteers in a clinical trial evaluating a candidate vaccine aimed at the B.1.351 SARS-CoV-2 variant.

For Serial Testing

The US Food and Drug Administration has authorized antigen tests for SARS-CoV-2 for use in serial testing of asymptomatic people.

In Nature this week: new single-cell RNA sequencing data preprocessing approach, and more.

The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.

The approach applies deep learning and could potentially be used to identify people with early-stage disease when therapies may have more of an effect.

The firm is using Mesa Biotech's Accula system for the testing, beginning Thursday, the start of the 2021 MLB season.

The company said that it is on track to meet its goal of shaving $7.2 million in costs this year as it undertakes a recently announced restructuring plan.

Fresh off a name change, the company last week introduced a monitoring platform for new SARS-CoV-2 variants that alerts diagnostic test makers to potential problems.


According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.